PDS Biotechnology Corporation (NASDAQ:PDSB) Q3 2024 Earnings Conference Call November 14, 2024 8:30 AM ET

Company Participants

Tom Johnson - LifeSci Advisors
Frank Bedu-Addo - Chief Executive Officer
Lars Boesgaard - Chief Financial Officer
Kirk Shepard - Chief Medical Officer

Conference Call Participants

Louise Chen - Cantor Fitzgerald
Ali Rashidfarrokhi - B. Riley
Robert LeBoyer - Noble Capital Markets

Operator

Good morning ladies and gentlemen and welcome to PDS Biotech's Third Quarter 2024 Results and Clinical Strategy Update Conference Call. All participants are currently in listen-only mode. Following the formal presentation, we'll open up the call for question-and-answer session.

I would now like to turn the conference over to Tom Johnson of LifeSci Advisors. Please go ahead, sir.

Tom Johnson

Thank you, operator and good morning everyone. Welcome to PDS Biotech's third quarter 2024 results and clinical strategy update call. I am joined on the call today by the following members of the company's management team, Dr. Frank Bedu-Addo, Chief Executive Officer; Dr. Kirk Shepard, Chief Medical Officer; and Lars Boesgaard, Chief Financial Officer. Dr. Bedu-Addo will begin with an overview of the company's recent interactions with investors, investigators and others regarding the clinical development plans. Mr. Boesgaard will review our financial results for the third quarter and Dr. Shepard will then join the call to help address questions from covering analysts.

As a reminder, during this call we will be making forward-looking statements, which are subject to various risks and uncertainties that could cause our actual results to differ materially from these statements. Any such statements should be considered in conjunction with the cautionary statements in our press releases and risk factors discussed in our filings with the SEC, including our Quarterly Reports on Form 10-Q and Annual Report on Form 10-K, and cautionary statements made during this call. We assume no obligation to update any of these forward-looking statements or information.

Now I'd like to turn the call over to Dr. Bedu-Addo. Frank?

Frank Bedu-Addo

Thank you, Tom and good morning everyone. It's our pleasure to speak with you again and to provide an update on our progress in advancing our clinical programs. Our third quarter has been a very busy and productive period. Since the update we provided on August 1^st, we have been actively engaged with investors and clinicians to discuss our funding requirements and strategy for our VERSATILE-003 Phase 3 trial.

VERSATILE-003 is evaluating Versamune HPV + pembrolizumab compared to pembrolizumab alone as a potential treatment for first line recurrent and/or metastatic HPV16-positive head and neck squamous cell carcinoma or HNSCC. I refer to this simply as head and neck cancer. I am very pleased to report that both investor and investigator interest in our VERSATILE-003 trial is strong.